Skip to content

LSD research published in 2022

Page 2 of 5: studies 21 to 40 of 85, newest first. Back to the LSD overview

Studies

Psychedelic drugs for psychiatric disorders.

Journal of the Neurological Sciences September 15, 2022 Sabrina Correa Da Costa, Tyler Oesterle, Teresa A Rummans et al. 21 citations

Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and...

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample

International Journal of Environmental Research and Public Health September 9, 2022 Christin Mellner, Micael Dahlen, Otto Simonsson 18 citations

Objectives: Absenteeism from work due to illness, and related costs, has increased steadily during the past decades. In recent years, there has been a reemergence of research on the therapeutic effects of classic psychedelics showing associations with both physical and mental health. However, the association between classic psychedelics and sick leave remains unknown. The aim of this study is...

DOI: 10.3390/ijerph191811353 (opens in new tab) Psilocybin Health economics Public health Sickness absence +7

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.

Experimental and Clinical Psychopharmacology September 1, 2022 Julie A E Christensen, David C. Fipps, J Michael Bostwick 4 citations

Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...

Psychedelics in the Treatment of Substance Use Disorders

Psychiatric Annals September 1, 2022 Brian S. Barnett, Jeremy Weleff 6 citations

Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...

Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.

Addictive Behaviors September 1, 2022 Kevin H. Yang, Benjamin H Han, Joseph J Palamar 30 citations

There is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mixed evidence regarding how use of such substances outside of medical settings relates to psychological distress, depression, and suicidality. We examined data from a US representative sample of noninstitutionalized adults from the 2015-2020 National...

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

Transcultural Psychiatry August 29, 2022 Ayse Ceren Kaypak, Amir Raz 17 citations

To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic intervention. This variation in...

Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying

PLoS One August 24, 2022 Mary M. Sweeney, Sandeep M. Nayak, Ethan Hurwitz et al. 60 citations

Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by...

Le traitement médiatique du LSD en France en 1966 : de la panique morale à la fin des études cliniques

Cygne Noir August 19, 2022 Zoë Dubus 3 citations

L’année 1966 voit l’apparition dans les médias français d’une nouvelle drogue aux effets présentés comme particulièrement délétères. Le LSD serait à l’origine de psychoses prolongées, de suicides, et mènerait la jeunesse américaine à se rebeller contre la société. Or, à cette époque, la substance est encore principalement un médicament et un outil d’étude du cerveau. Des milliers d’articles...

Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?

Journal of Humanistic Psychology August 18, 2022 Mark Molumby, Keith Gaynor, Suzanne Guérin et al. 3 citations

Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the validity of Carhart-Harris and Nutt’s (2017) model of extra-pharmacological (EP) factors. It examined whether such factors should be considered in any psychological suitability test for medicinally prescribed psilocybin. Two hundred nineteen...

Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP

Addiction August 17, 2022 Ofir Livne, Dvora Shmulewitz, Claire A Walsh et al. 90 citations

Abstract Background and Aims Hallucinogen use is potentially harmful. Information on whether such use has increased in recent decades is lacking. This study assessed overall and age‐specific time trends in the prevalence of 12‐month hallucinogen use in the US general population. Design Cross‐sectional. Setting Data from the US National Survey on Drug Use and Health, 2002–19. Participants...

Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data

Journal of Psychopharmacology August 16, 2022 Brian S. Barnett, Kathleen M Ziegler, Rick Doblin et al. 15 citations

BACKGROUND: In 1967, concerns about the carcinogenic potential of psychedelics arose after a study reported chromosomal damage in human leukocytes following in vitro lysergic acid (LSD) exposure. Worries were further heightened by subsequent reports of leukemia and other cancers in LSD users. Additional investigations of psychedelics' effects on chromosomes were published over the next decade,...

Estigmas do tratamento com LSD: um estudo exploratório

Revista Pesquisa Qualitativa August 6, 2022 Veronica Candaten Furini, William Weber Ceconello

A Dietilamida do Ácido Lisérgico (LSD) é uma substância psicoativa, capaz de causar mudanças cognitivas. Ganhou notoriedade nos anos 1960, sendo interligada à cultura hippie. Seu uso foi proibido e considerado nocivo à população, gerando estigmas e preconceitos acerca de substâncias psicoativas no geral. O objetivo foi levantar opiniões a respeito do uso terapêutico do LSD. Trata-se de uma...

Psychedelics and Facial Expressions: the impact of an LSD microdose on the process of encoding emotional facial expressions

University of Chicago August 1, 2022 Alicia Rowland

While LSD may have had a harsh reputation in decades previous, current research has been investigating its potential as a therapeutic modality. It has been shown that full doses of LSD are capable of providing therapeutic effects however, the concept of "microdosing", or the repeated use of very low doses has become increasingly popular. Yet, the literature does not provide consistent results...

DOI: 10.6082/9w10z-k1e64 (opens in new tab) Electroencephalography Scalp Placebo Oddball paradigm +8

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

Journal of Palliative Medicine August 1, 2022 William E Rosa, Zachary Sager, Megan Miller et al. 49 citations

Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...

Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice.

ACS Chemical Neuroscience July 28, 2022 Mario de la Fuente Revenga, Alaina M Jaster, John McGinn et al.

Classical psychedelics represent a subgroup of serotonergic psychoactive substances characterized by their distinct subjective effects on the human psyche. Another unique attribute of this drug class is that such effects become less apparent after repeated exposure within a short time span. The classification of psychedelics as a subgroup within the serotonergic drug family and the tolerance to...

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study

Psychiatry Research Case Reports July 15, 2022 Mika Turkia 14 citations

This article describes a case of a teenager with early complex trauma due to chronic domestic violence. Cannabis use triggered auditory hallucinations, after which the teenager was diagnosed with an acute schizophrenia-like psychotic disorder. Antipsychotic medication did not fully resolve symptoms. Eventually the teenager chose to self-medicate with LSD in order to resolve a suicidal...

DOI: 10.1016/j.psycr.2022.100029 (opens in new tab) Cannabis Psychosis Antipsychotic Schizophrenia object-oriented programming +2

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy

CNS Spectrums July 11, 2022 Seetal Dodd, Trevor R. Norman, Harris A. Eyre et al. 61 citations

Abstract Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to...

Psychedelics in the treatment of unipolar and bipolar depression

International Journal of Bipolar Disorders July 5, 2022 Oliver G. Bosch, Simon Halm, Erich Seifritz 35 citations

Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory...

Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice.

Journal of Psychopharmacology July 2022 Lauri Elsilä, Juliana Harkki, Emma Enberg et al.

Psychedelics, like lysergic acid diethylamide (LSD), are again being studied as potential therapies for many neuropsychiatric disorders, including addictions. At the same time, the acute effects of psychedelics on rewarding behaviours have been scarcely studied. The current study aimed to clarify if LSD decreases binge-like ethanol drinking in mice, and whether the observed acute effects on...

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.

Neuroscience & Biobehavioral Reviews July 1, 2022 Drummond E-Wen Mcculloch, Gitte Moos Knudsen, Frederick Streeter Barrett et al. 14 citations

Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in neural pathways in clinical and healthy populations. Here we, a large group of psychedelic imaging researchers, review the 42 research...